Cargando…
The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue
BACKGROUND: Erectile dysfunction (ED) is a relatively frequent disease that negatively impacts the overall quality of life, well‐being, and relationships. Although the use of phosphodiesterase 5 inhibitors (PDE5is) has revolutionized the treatment of ED, a high percentage of ED patients discontinue...
Autores principales: | Zucchi, A., Costantini, E., Scroppo, F. I., Silvani, M., Kopa, Z., Illiano, E., Petrillo, M. G., Cari, L., Nocentini, G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790582/ https://www.ncbi.nlm.nih.gov/pubmed/31350821 http://dx.doi.org/10.1111/andr.12683 |
Ejemplares similares
-
Evaluation of SARS-CoV-2 and semen quality in COVID-19 patients
por: Scroppo, F.I., et al.
Publicado: (2021) -
Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
por: Giembycz, Mark A, et al.
Publicado: (2010) -
First‐in‐human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males
por: Moschetti, Viktoria, et al.
Publicado: (2016) -
Methylxanthines and Phosphodiesterase Inhibitors in the Treatment of Airways Disease
por: Semple, S J G
Publicado: (1995) -
Evolution of Phosphodiesterase-5 Inhibitors
por: Moon, Du Geon
Publicado: (2015)